

To print: Select File and then Print from your browser's menu

Title: **New Monoclonal Antibody Effective Treatment For Crohn's Disease Therapy**

URL: <http://www.pslgroup.com/dg/2802E.htm>

Doctor's Guide

May 13, 1997


WASHINGTON, and MALVERN, Pa., May 13, 1997 -- Statistically significant results were released yesterday from two controlled clinical studies testing cA2(TM) (infliximab), a monoclonal antibody, in the treatment of Crohn's disease, a chronic disorder characterized by inflammation of the gastrointestinal tract. Data from both trials show that treatment with cA2 can have a beneficial effect on both the severity and number of symptoms associated with Crohn's disease.

"This kind of clinical response in Crohn's disease is unprecedented," said Stephan Targan, M.D., principal investigator and Director of the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in Los Angeles, "and provides compelling evidence of the potential of cA2 in the treatment of Crohn's disease."

The results of these trials, which were conducted in 18 centers in North America and Europe, were announced today during Digestive Disease Week in Washington, DC. Digestive Disease Week is sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy and The Society for Surgery of the Alimentary Tract. Last year, during Digestive Disease Week, Centocor released data showing a statistically significant improvement in disease activity following a single infusion of cA2. In the initial study, 65 percent of patients treated with cA2 achieved a clinical response and 33 percent of patients went into remission within four weeks of the start of treatment.

In the extension phase of this study, known as T16, which is being reported today, additional cA2 treatments were demonstrated to maintain Crohn's disease patients in clinical remission as measured by the CDAI, the Crohn's disease activity index.

<http://www.docguide.com/dg.ns/PrintPrint/815D53A771190A4285256496004B0796>



In the initial phase of the T16 trial, the median CDAI of treated patients dropped from 312 to 125 eight weeks after a single cA2 infusion. Following four additional infusions, given eight weeks apart in the most recent phase of the T16 trial, cA2 maintained the CDAI reduction, with median CDAI eight weeks following the final treatment at 117 (CDAI<150 constitutes disease remission).

Data from the second trial, named T20, indicate that cA2 may be a valuable treatment for enterocutaneous fistulae, a painful, debilitating complication of Crohn's disease in which extensions occur between the bowel and the skin, mostly in the perianal area, causing drainage of mucous and/or fecal material. In this trial, approximately two-thirds of participants experienced closure of at least 50 percent of their fistulae.

In both clinical trials, onset of cA2 clinical benefit was rapid with the vast majority of responders achieving response within two weeks. In addition, cA2 was generally well tolerated in these two trials. "We have been following these studies with great interest," said Richard P. MacDermott, M. D., Immediate Past Chairperson, National Scientific Advisory Committee, Crohn's & Colitis Foundation of America (CCFA). "The results are very encouraging. It is possible that an important new therapy for Crohn's disease may be on the horizon."

In the T16 study, 73 patients who showed a clinical response eight weeks after their initial infusion of cA2 were re-randomized at week 12 to further treatment with cA2 or placebo, and infused every eight weeks for a total of four additional infusions. Those patients re-randomized to cA2 continued to experience an improvement in symptoms from baseline assessment and the percentage of patients achieving clinical remission was maintained at approximately 60 percent during the re-treatment period.

Those patients who responded to their initial infusion of cA2 and then received placebo in the re-treatment phase of the study, experienced a gradual decline in clinical effect over time. However, 19 percent of the placebo group were still in remission 48 weeks after their initial cA2 infusion.

The second study, T20, was conducted with 94 patients with draining enterocutaneous fistulae. Following a series of three cA2 infusions given two and four weeks apart, two-thirds of patients experienced closure of at least 50 percent of their fistulas ($P=0.002$). These patients had previously failed to respond adequately to treatment with combinations of corticosteroids, methotrexate, 6-MP/azathioprine, aminosalicylates, or antibiotics. These underlying therapies were given in conjunction with the cA2 infusions in this study. "cA2 is the first drug to ever demonstrate statistical significance in a controlled trial to close fistulas," according to Daniel Present, M.D., principal investigator and Clinical Professor of Medicine at Mount Sinai.

cA2, a monoclonal antibody, is the first of a revolutionary class of agents being studied for Crohn's disease. It is a well-tolerated, highly selective treatment that blocks activity of a key inflammatory mediator called tumor necrosis factor or TNF. cA2 is also being studied for treatment of rheumatoid arthritis.

Centocor is a biotechnology company whose mission is to develop and commercialize novel therapeutic and diagnostic products and services that solve critical needs in human health care. The company concentrates on research and development, manufacturing and market development, with a primary technology focus on monoclonal antibodies and DNA-based products.

More information about the company and cA2 can be found on Centocor's home page located at the following address. For more information about Crohn's disease or ulcerative colitis, a related disorder, contact the Crohn's & Colitis Foundation of America, at 1-800-343-3637 (website: <http://www.ccfafa.org>).

Copyright © 1999 P\SVL Consulting Group Inc. All rights reserved. Republication or redistribution of P\SVL content is expressly prohibited without the prior written consent of P\SVL. P\SVL shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.

This news story was printed from *Doctor's Guide to the Internet* located at <http://www.docguide.com>

[Return to News Story Page](#)

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\SVL Consulting Group Inc.
All rights reserved.